Latest Breaking News On - Plasma alliance - Page 3 : comparemela.com

Takeda, CSL to end alliance as plasma-based COVID-19 drug fails key test

CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine

CoVIg-19 Plasma Alliance Saturday, April 3, 2021 2:00PM IST (8:30AM GMT)   Osaka, Japan & King of Prussia, Pa., United States:    Phase 3 Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC) Clinical Trial Sponsored and Funded by the National Institute of Allergy and Infectious Diseases (NIAID), Part of the National Institutes of Health (NIH), Did Not Meet Its Endpoints to Show Efficacy in Adults Hospitalized With COVID-19 The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints. No serious safety signals were raised in the trial.

03 April 2021 Coronavirus Charts and News: Scientists Identify Nine Potential New COVID-19 Treatments

The U.S. new cases 7-day rolling average are 6.5 % HIGHER than the 7-day rolling average one week ago and U.S. deaths due to coronavirus are now 13.5 % LOWER than the rolling average one week ago. Today s posts include: U.S. Coronavirus New Cases are 68,844 U.S. Coronavirus deaths are at 961 U.S. Coronavirus immunizations have been administered to 47.1 % of the population The 7-day rolling average rate of growth of the pandemic shows new cases improved and deaths improved Just How Much Was 2020 an Outlier for Deaths? The Pandemic s Wrongest Man CDC announces next phase of cruise ship guidance A vaccine fiasco damages Europe s credibility

Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19

CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine